VYVGART HYTRULO
VYVGART HYTRULO is a combination therapy indicated for the treatment of specific autoimmune disorders in adult patients. It is approved for use in adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. The medication is also indicated for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). As a coformulation of a neonatal Fc receptor blocker and an endoglycosidase, it provides a therapeutic option for managing these chronic neuromuscular and neurological conditions.
How VYVGART HYTRULO Works
The medication consists of efgartigimod alfa, which binds to the neonatal Fc receptor (FcRn) to reduce circulating IgG levels. By blocking this receptor, the drug decreases the presence of antibodies that contribute to disease pathology. The second component, hyaluronidase, is an endoglycosidase that depolymerizes hyaluronan to increase the permeability of subcutaneous tissue. This effect facilitates drug delivery and is transient, with tissue permeability returning to normal within 24 to 48 hours.
Details
- Status
- Prescription
- First Approved
- 2023-06-20
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
VYVGART HYTRULO Approval History
What VYVGART HYTRULO Treats
2 indicationsVYVGART HYTRULO is approved for 2 conditions since its original approval in 2023. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Myasthenia Gravis
- Chronic Inflammatory Demyelinating Polyneuropathy
Drugs Similar to VYVGART HYTRULO
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
VYVGART HYTRULO FDA Label Details
ProIndications & Usage
FDA Label (PDF)VYVGART HYTRULO is indicated for the treatment of adult patients with: generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive chronic inflammatory demyelinating polyneuropathy (CIDP) VYVGART HYTRULO is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase, indicated for the treatment of adult patients with: generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive chronic inflammatory demyelinating polyneuropathy (CIDP)
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.